ReviewClinical ophthalmology (Auckland, N.Z.)2019
Central Serous Chorioretinopathy: Pathogenesis and Management.
Review in Clinical ophthalmology (Auckland, N.Z.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 2 syntheses or guidelines pooled it, 99 citations in OpenAlex.
- Efficacy and safety of subthreshold micropulse laser for chronic central serous chorioretinopathy: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Ocular manifestations of obstructive sleep apnea: a systematic review and meta-analysis.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2024Pooled it
- Oral eplerenone in first-episode acute central serous chorioretinopathy: results of a double-masked randomized trial.International ophthalmology · 2026Trial
- Factors affecting resolution of subretinal fluid after selective retina therapy for central serous chorioretinopathy.Scientific reports · 2021Trial
- Efficacy of Photodynamic Therapy in Chronic Central Serous Chorioretinopathy: A Retrospective Analysis at Hanusch Hospital, Vienna.Klinische Monatsblatter fur Augenheilkunde · 2026Article
- Efficacy and safety of 577 nm subthreshold laser treatment in acute central serous chorioretinopathy.BMC ophthalmology · 2026Article
- Central Serous Chorioretinopathy Following Corticosteroid Injection for Thumb Carpometacarpal Osteoarthritis: A Case Report.Journal of orthopaedic case reports · 2026Article
- Dogs with sudden acquired retinal degeneration syndrome have evidence of a hypercoagulable state and decreased clot turnover.Journal of the American Veterinary Medical Association · 2026Article
- Histopathologic and ultrastructural features of the choriocapillaris in dogs with sudden acquired retinal degeneration syndrome and progressive retinal atrophy.Veterinary pathology · 2026Article
- Treatment of Central Serous Chorioretinopathy With Topical Difluprednate: A Literature Review.Cureus · 2026Review
- Clinical and multimodal imaging characteristics of acute central serous chorioretinopathy with fibrinous exudation.International journal of ophthalmology · 2026Article
- Treatment of central serous chorioretinopathy: new options for an old disease.Eye (London, England) · 2025Review
- Comparative efficacy of subthreshold micropulse laser versus conventional laser therapy in central serous chorioretinopathy.Lasers in medical science · 2025Article
- Association between subretinal fluid duration in central serous chorioretinopathy and chorioretinal structure in unaffected fellow eyes.Scientific reports · 2025Article
- Quantitative Changes in Vascular and Neural Fibers Induced by Subretinal Fluid Excluding the Peripapillary Region in Patients with Chronic Central Serous Chorioretinopathy.Diagnostics (Basel, Switzerland) · 2025Article
- Diabetic Retinopathy - Pathophysiology to Treatment: A Review.Current diabetes reviews · 2025Review
- A Comparative Study on the Prevalence ofClinical ophthalmology (Auckland, N.Z.) · 2025Article
- Influence of combined eplerenone, aflibercept and nepafenac therapy on central serous chorioretinopathy.International journal of ophthalmology · 2025Article
- Dysthyroid optic neuropathy treated with tocilizumab.Endocrinology, diabetes & metabolism case reports · 2025Article
- A dataset of color fundus images for the detection and classification of eye diseases.Data in brief · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Central serous chorioretinopathy (CSC) is a common retina disease and has a relative high recurrence rate, etiology, and pathogenesis of which remains largely ambiguous. The effects on the retina are usually self-limited, although some people are left with permanent vision loss due to progressive and irreversible photoreceptor damage or retinal pigment epithelium atrophy. There have been a number of interventions used in CSC, including, but not limited to, laser treatment, photodynamic therapy (PDT), intravitreal injection of anti-vascular endothelial growth factor agents, and subthreshold lasers. It is not clear whether there is a clinically important benefit to treating acute CSC, which often resolves spontaneously as part of its natural history. Of the interventions studied to date, PDT and micropulse laser treatment appear the most promising. .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.